Belapectin
- Generic Name
- Belapectin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1980787-47-0
- Unique Ingredient Identifier
- K7ODU55HT6
- Background
Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).
- Associated Conditions
- -
- Associated Therapies
- -
Belapectin Misses Primary Endpoint in Phase 3 MASH Cirrhosis, Portal Hypertension Trial
The NAVIGATE trial of Galectin Therapeutics' belapectin for MASH cirrhosis and portal hypertension missed its primary endpoint for varices prevention. Belapectin reduced varice incidence but not significantly. Further analysis and 36-month treatment data expected in 2025.
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin Therapeutics' stock dropped 35% after its lead asset, Belapectin, failed to reach the primary endpoint in a Phase IIb/III trial for MASH cirrhosis. While Belapectin reduced varices incidence by 48.9% in the per-protocol population, it fell short of the 52.5% target. The drug showed a highly encouraging safety profile and potential in advanced melanoma. Galectin plans to analyze 36-month outcomes before determining next steps.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath